107.20
8.80 (8.94%)
Previous Close | 98.40 |
Volume | 174,070 |
Avg. Volume (3M) | 3,910,633 |
Market Cap | 1,024,239,104 |
Price / Sales | 8.87 |
Price / Book | 2.97 |
52 Weeks Range | |
Earnings Date | 4 Mar 2025 |
Profit Margin | -79.80% |
Operating Margin (TTM) | -75.99% |
Diluted EPS (TTM) | -0.160 |
Quarterly Revenue Growth (YOY) | 18.50% |
Total Debt/Equity (MRQ) | 7.84% |
Current Ratio (MRQ) | 4.66 |
Operating Cash Flow (TTM) | -109.89 M |
Levered Free Cash Flow (TTM) | -82.20 M |
Return on Assets (TTM) | -12.53% |
Return on Equity (TTM) | -23.77% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (GB) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Bearish | |
Stock | OXFORD NANOPORE TECHNOLOGIES PL | - | - |
AIStockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -0.5 |
Average | -0.63 |
Similar Stocks
Stock | Market Cap | DY | P/E (TTM) | P/B |
---|---|---|---|---|
OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 42.94% |
% Held by Institutions | 43.11% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |